TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32732745

Group type: EXPERIMENTAL
Intervention: Ozone injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 40
Study: 35367469

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 20 μg/m3
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 50 μg/m3
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 150 μg/m3
Number of subjects: 13

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 13
Study: 33894833

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 1064
Study: 34304516

Group type: EXPERIMENTAL
Intervention: ICG combined with methylene blue (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Only methylene blue (Group B)
Number of subjects: 90
Study: 33861813

Group type: EXPERIMENTAL
Intervention: Game-based social-emotional programme (emoTIC)
Number of subjects: 119
Study: 35217941

Group type: EXPERIMENTAL
Intervention: 120-µm cap thickness
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 140-µm cap thickness
Number of subjects: 94

Group type: COMPARATOR
Intervention: Both 120-µm and 140-µm cap thicknesses
Number of subjects: 94
Study: 32847731

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Ultrabiotic 60™ and Saccharomyces boulardii during international competition)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 35799654

Group type: EXPERIMENTAL
Intervention: Fenestration decompression
Number of subjects: 135

Group type: COMPARATOR
Intervention: Curettage of cysts
Number of subjects: 135
Study: 33432422

Group type: EXPERIMENTAL
Intervention: High‐Security Vitrification™ - HSV
Number of subjects: 737

Group type: COMPARATOR
Intervention: Cryotop® open system
Number of subjects: 737
Study: 33935064

Group type: EXPERIMENTAL
Intervention: Workplace counseling program with a physical therapist or nurse once a week for 12 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Workplace counseling program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 37
Study: 33819528

Group type: EXPERIMENTAL
Intervention: Combined intervention targeting loss of control over eating (inhibitory control training and implementation intentions)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Food-specific or general intervention
Number of subjects: 78
Study: 32540090

Group type: EXPERIMENTAL
Intervention: Classwide math intervention
Number of subjects: 537
Study: 36087008

Group type: EXPERIMENTAL
Intervention: Batoclimab 680 mg with IVMP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg with IVMP
Number of subjects: 9

Group type: COMPARATOR
Intervention: IVMP alone (control group not explicitly mentioned)
Number of subjects: 9
Study: 33043845

Group type: EXPERIMENTAL
Intervention: Preoperative temporal bone CT showing a small facial recess
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Preoperative temporal bone CT showing a prominent sigmoid sinus
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Preoperative MRI brain and internal auditory canal findings
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Preoperative CT findings
Number of subjects: 91
Study: 32220153

Group type: EXPERIMENTAL
Intervention: Perphenazine, Quetiapine, Risperidone, Ziprasidone
Number of subjects: 1338

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1338

Group type: EXPERIMENTAL
Intervention: SZ + AUD
Number of subjects: 1338
Study: 35547000

Group type: EXPERIMENTAL
Intervention: Chiglitazar (32 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Chiglitazar (48 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 81
Study: 33198702

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 110

Group type: COMPARATOR
Intervention: Supervised training
Number of subjects: 110
Study: 33899090

Group type: EXPERIMENTAL
Intervention: Nurse-driven health and lifestyle modification programme
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard care and general information about risk factor management (Control)
Number of subjects: 256
Study: 32192799

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4795

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4795
Study: 35933966

Group type: EXPERIMENTAL
Intervention: High resolution, high contrast MRI for neurovascular contact assessment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (47 controls)
Number of subjects: 94
Study: 33710299

Group type: EXPERIMENTAL
Intervention: 10 mg of the oral GABA reuptake inhibitor tiagabine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 35981820

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy with conservative management
Number of subjects: 4480

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy with invasive management
Number of subjects: 4480
Study: 33616303

Group type: EXPERIMENTAL
Intervention: Synthetic CT (sCT) software for general pelvis anatomy developed by Philips Healthcare.
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Synthetic CT (sCT) software for general pelvis anatomy.
Number of subjects: 147
Study: 32541132

Group type: EXPERIMENTAL
Intervention: Hydrogen (H2) therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no H2 therapy)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: H2 + chemotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: H2 + targeted therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: H2 + immunotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combined therapy groups (H2 with chemotherapy, targeted therapy, or immunotherapy)
Number of subjects: 58
Study: 35738852

Group type: EXPERIMENTAL
Intervention: Ranolazine treatment
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Ranolazine treatment in patients with cardiac resynchronization therapy (CRT) ICDs
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Ranolazine treatment in patients with ICDs without CRT
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Concomitant AAD therapy
Number of subjects: 1012
Study: 32698681

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 157

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 157
Study: 33177429

Group type: EXPERIMENTAL
Intervention: Various surgical treatments for tibial plateau fractures
Number of subjects: 2106

Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis
Number of subjects: 2106
Study: 35307131

Group type: EXPERIMENTAL
Intervention: HOB elevation to 30 degrees
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: HOB elevation to 15 degrees
Number of subjects: 307

Group type: COMPARATOR
Intervention: HOB 0 degree (control group)
Number of subjects: 307
Study: 32327093

Group type: COMPARATOR
Intervention: Normal weight (BMI <25 kg/m2)
Number of subjects: 2238

Group type: EXPERIMENTAL
Intervention: Overweight (25 kg/m2 ≤BMI <30 kg/m2)
Number of subjects: 2238

Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30 kg/m2)
Number of subjects: 2238
Study: 34016658

Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition until extubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6-hour fasting prior to extubation
Number of subjects: 0
Study: 32183390

Group type: EXPERIMENTAL
Intervention: 5% O2
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20% O2
Number of subjects: 0
Study: 35671862

Group type: EXPERIMENTAL
Intervention: Helminthostachys zeylanica (HZ) for 42 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (control group) for 42 days
Number of subjects: 45
Study: 33451253

Group type: EXPERIMENTAL
Intervention: Eccentric loading program followed by stretching exercises combined with extracorporeal shockwave therapy (ESWT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham ESWT
Number of subjects: 50
Study: 32223566

Group type: EXPERIMENTAL
Intervention: Ayurvedic multiherbal medication administered daily for 1 month followed by 5 months of oral medication.
Number of subjects: 52
Study: 35557490

Group type: EXPERIMENTAL
Intervention: lenalidomide/bortezomib/dexamethasone
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Heparin administration
Number of subjects: 700
Study: 33091863

Group type: EXPERIMENTAL
Intervention: Total liver volume (T), left liver volume (L), right liver volume (R), caudate liver volume (C), spleen volume (S), L/T ratio, C/T ratio
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Caudate liver volume (C), spleen volume (S), C/T ratio
Number of subjects: 165
Study: 36129886

Group type: EXPERIMENTAL
Intervention: Jewelry-making sessions held twice a week for four weeks
Number of subjects: 62
Study: 34474096

Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of LV end-diastolic volume index (EDVI) using traditional approach
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of LV end-diastolic volume index (EDVI) using recommended approach
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of aortic end-diastolic flow velocity (EDFV)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Positive/negative likelihood ratios for ruling in/ruling out severe AR using EDVI (traditional)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Positive/negative likelihood ratios for ruling in/ruling out severe AR using EDVI (recommended)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Positive/negative likelihood ratios for ruling in/ruling out severe AR using EDFV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Using derived cut-off values instead of >2 SD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Using EDFV ≤10 cm/s instead of ≤20 cm/s
Number of subjects: 120
Study: 35544239

Group type: EXPERIMENTAL
Intervention: Zuranolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34255246

Group type: EXPERIMENTAL
Intervention: Esophagectomy
Number of subjects: 9594

Group type: COMPARATOR
Intervention: Total Gastrectomy
Number of subjects: 9594

Group type: COMPARATOR
Intervention: Total Gastrectomy (after matching)
Number of subjects: 9594

Group type: EXPERIMENTAL
Intervention: Esophagectomy (after matching)
Number of subjects: 9594

Group type: COMPARATOR
Intervention: Total Gastrectomy vs Esophagectomy (adjusted analyses)
Number of subjects: 9594
Study: 33446284

Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-adrenergic antagonist)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 34047403

Group type: EXPERIMENTAL
Intervention: Bilateral transversus thoracis muscle plane blocks (TP group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 60
Study: 35202974

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus ramucirumab (arm A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: paclitaxel plus ramucirumab (arm B)
Number of subjects: 110
Study: 32835877

Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid-mediated Photodynamic Therapy (5-ALA-PDT)
Number of subjects: 80
Study: 33001138

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 600 mg daily for 8 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo, size-matched, taken orally for 8 weeks
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 35657073

Group type: EXPERIMENTAL
Intervention: 2-day course of levofloxacin
Number of subjects: 310

Group type: COMPARATOR
Intervention: 7-day course of levofloxacin
Number of subjects: 310
Study: 33969792

Group type: EXPERIMENTAL
Intervention: Vancomycin-heparin-lock
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-heparin, high-dose vancomycin-lock
Number of subjects: 25
Study: 32729820

Group type: COMPARATOR
Intervention: JY09 6.0 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: JY09 (various doses 0.3, 0.7, 1.5, 3.0, and 6.0 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: JY09
Number of subjects: 5
Study: 35431250

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) for 12 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 56
Study: 34171938

Group type: EXPERIMENTAL
Intervention: AS201‐01 tablets (4 tablets, twice daily for 4 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tablets (4 tablets, twice daily for 4 days)
Number of subjects: 30
Study: 34266839

Group type: EXPERIMENTAL
Intervention: ABCDEF bundle protocol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-protocolised standard care
Number of subjects: 150
Study: 33074283

Group type: EXPERIMENTAL
Intervention: Medicaid-focused plan
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Commercial managed care plan
Number of subjects: 8010
Study: 33855879

Group type: EXPERIMENTAL
Intervention: Nerve and tendon gliding exercises in addition to wrist splint use
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wrist splint use only
Number of subjects: 80
Study: 32623839

Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: metformin 1,000‐1,500 mg daily
Number of subjects: 0
Study: 32447796

Group type: EXPERIMENTAL
Intervention: Work-private life conflicts
Number of subjects: 3398

Group type: EXPERIMENTAL
Intervention: Opportunities for development and behaviour of the direct line manager
Number of subjects: 3398
Study: 36175904

Group type: EXPERIMENTAL
Intervention: Playing lullaby for mother (B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Playing lullaby for a mother while holding a photo of her own baby (C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 100
Study: 35501887

Group type: EXPERIMENTAL
Intervention: Trained community‐oriented resource persons (CORPs) conducting community‐based screening of BP, referral, diagnosis confirmation, initial treatment, monthly home‐based follow-up care, and health education.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (diagnosis, treatment and follow‐up care in hospital of a patient’s choice).
Number of subjects: 200
Study: 34817082

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 33958325

Group type: EXPERIMENTAL
Intervention: Tight-control/treat-to-target strategy (TC/T2T) with visits every 4 weeks and treatment intensification until achieving ASDAS <2.1
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (UC) with visits every 12 weeks and treatment at the rheumatologist's discretion
Number of subjects: 160
Study: 32929684

Group type: EXPERIMENTAL
Intervention: Early shunt embolization (ESE)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Late shunt embolization (LSE)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard medical care (Control)
Number of subjects: 67
Study: 34743379

Group type: EXPERIMENTAL
Intervention: Nutrison Protein Plus Multifibre®
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diason®
Number of subjects: 35

Group type: COMPARATOR
Intervention: Glucerna Select®
Number of subjects: 35
Study: 34521465

Group type: EXPERIMENTAL
Intervention: MED intervention (medication review by a pharmacist and geriatrician in the ED)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MULTI‐NUT‐MED intervention (MED intervention + dietary counseling and individualized interventions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: eGFR equations
Number of subjects: 200
Study: 35137699

Group type: EXPERIMENTAL
Intervention: Antipsychotics (off-label use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinuation of antipsychotics after 4 months
Number of subjects: 0
Study: 34325984

Group type: EXPERIMENTAL
Intervention: Nasal breathing through a damp gauze for 10 minutes during vocal warm-up exercises
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vocal warm-up exercises without hydration procedures for 10 minutes
Number of subjects: 61

Group type: COMPARATOR
Intervention: Talking using normal speaking voice for 10 minutes
Number of subjects: 61
Study: 35014601

Group type: EXPERIMENTAL
Intervention: FMT alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rifaximin (R-FMT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Metronidazole (CM-FMT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo FMT
Number of subjects: 44
Study: 36198262

Group type: EXPERIMENTAL
Intervention: Eligible group (n=103)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Ineligible group (n=104)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Eligible group
Number of subjects: 207
Study: 33567589

Group type: EXPERIMENTAL
Intervention: Water Replenishment Group 1 (1000 mL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Water Replenishment Group 2 (500 mL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Water Replenishment Group 3 (200 mL)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-Replenishment Group (NR)
Number of subjects: 76
Study: 35082003

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study: 33631326

Group type: EXPERIMENTAL
Intervention: Spiritual Distress and Resources Questionnaire (SDRQ)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Test-retest reliability of SDRQ
Number of subjects: 219
Study: 36076107

Group type: EXPERIMENTAL
Intervention: Inhaled vanilla essential oil (VEO)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Inhaled lavender essential oil (LEO)
Number of subjects: 142
Study: 34737452

Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus fulvestrant
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 361
Study: 36151441

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase before endovascular treatment
Number of subjects: 649

Group type: COMPARATOR
Intervention: Endovascular treatment only
Number of subjects: 649
Study: 36326154

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA) with obturator nerve block (ONB) using plain Bupivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: General anaesthesia (GA) with muscle relaxation
Number of subjects: 72
Study: 32483851

Group type: EXPERIMENTAL
Intervention: unsupervised pelvic floor muscle training (PFMT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: lecture with no PFMT
Number of subjects: 73
Study: 32729749

Group type: EXPERIMENTAL
Intervention: OrganOx metra
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 0
Study: 36481203

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 31
Study: 34043280

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 98
Study: 32539893

Group type: COMPARATOR
Intervention: CS200 (200 mg CS per kg feed)
Number of subjects: 320

Group type: COMPARATOR
Intervention: CS100 (100 mg CS per kg feed)
Number of subjects: 320
Study: 35014145

Group type: EXPERIMENTAL
Intervention: Triple Therapy (metformin/exenatide/pioglitazone)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional Therapy (metformin → glipizide → glargine insulin)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional Therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Triple Therapy
Number of subjects: 68
Study: 33967075

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (VRT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 35026362

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided suprainguinal fascia iliaca block (SFIB) + sham AQLB
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ultrasound-guided anterior quadratus lumborum block (AQLB) + sham SFIB
Number of subjects: 100
Study: 36401070

Group type: EXPERIMENTAL
Intervention: CAF + CGF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CAF + A-PRF
Number of subjects: 16

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 16
Study: 34495065

Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (group H)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard-voltage pulsed radiofrequency (group S)
Number of subjects: 64
Study: 32394855

Group type: EXPERIMENTAL
Intervention: Selexipag (doses: 1200‐1600 µg b.i.d., 600‐1000 µg b.i.d., 200‐400 µg b.i.d.)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 26
Study: 35251561

Group type: EXPERIMENTAL
Intervention: EPOC training in addition to conventional medication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional hypertension medication
Number of subjects: 60
Study: 34034929

Group type: EXPERIMENTAL
Intervention: CNS-directed therapy comprising four to 11 courses of i.v. methotrexate (5 g/m2) and 10 to 19 intrathecal chemotherapy injections, depending on risk group and CNS status.
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: CNS-3 status
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: CNS-directed therapy
Number of subjects: 1930
Study: 32020813

Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator spirometry
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator spirometry
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: GOLD criteria
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Moderate to severe disease
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Treatment status
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Symptom reporting
Number of subjects: 1015
Study: 36435746

Group type: EXPERIMENTAL
Intervention: Intervention 1 (recommendations summary)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Intervention 2 (recommendations summary and personalized feedback)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: All interventions (Intervention 1 and Intervention 2)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Alternatively funded providers
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Providers with a reduction in antibiotic prescribing
Number of subjects: 239